COVID -19 associated candidemia: from a shift in fungal epidemiology to a rise in azole drug resistance.
Candida parapsilosis
ERG11
Azole resistance
COVID-19-associated candidemia
Y132F
Journal
Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835
Informations de publication
Date de publication:
23 Mar 2024
23 Mar 2024
Historique:
medline:
24
3
2024
pubmed:
24
3
2024
entrez:
24
3
2024
Statut:
aheadofprint
Résumé
Our understanding of fungal epidemiology and the burden of antifungal drug resistance in COVID-19-associated candidemia (CAC) patients is limited. Therefore, we conducted a retrospective multicenter study in Iran to explore clinical and microbiological profiles of CAC patients. Yeast isolated from blood, were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and subjected to antifungal susceptibility testing (AFST) using the broth microdilution method M27-A3 protocol. A total of 0.6% of the COVID-19 patients acquired CAC (43/6174). Fluconazole was the most widely used antifungal, and 37% of patients were not treated. Contrary to historic candidemia patients, C. albicans and C. tropicalis were the most common species. In vitro resistance was high and only noted for azoles; 50%, 20%, and 13.6% of patients were infected with azole-non-susceptible (ANS) C. tropicalis, C. parapsilosis, and C. albicans isolates, respectively. ERG11 mutations conferring azole resistance were detected for C. parapsilosis isolates (Y132F), recovered from an azole-naïve patient. Our study revealed an unprecedented rise in ANS Candida isolates, including the first C. parapsilosis isolate carrying Y132F, among CAC patients in Iran, which potentially threatens the efficacy of fluconazole, the most widely used drug in our centers. Considering the high mortality rate and 37% of untreated CAC cases, our study underscores the importance of infection control strategies and antifungal stewardship to minimize the emergence of ANS Candida isolates during COVID-19. The mortality rate for patients with COVID-19-associated candidemia (CAC) is high. Fluconazole was the most widely used antifungal but candidemia with azole-non-susceptible Candida species are increasing.
Autres résumés
Type: plain-language-summary
(eng)
The mortality rate for patients with COVID-19-associated candidemia (CAC) is high. Fluconazole was the most widely used antifungal but candidemia with azole-non-susceptible Candida species are increasing.
Identifiants
pubmed: 38521982
pii: 7634360
doi: 10.1093/mmy/myae031
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.